Threshold Pharmaceuticals (THLD) Data Demonstrates Candidate Potential
Threshold Pharmaceuticals Inc., a biotech company focused on building a pipeline of drugs superior to conventional anticancer drugs, recently announced its ongoing phase III clinical trial results for its clinical stage hypoxia-activated prodrug, TH-302, which were presented at the Connective Tissue Oncology Society (CTOS) Meeting in Chicago. Sant P. Chawla, M.D., of the Sarcoma Oncology Center in Santa Monica and principal investigator for the study, gave the oral presentation summarizing the phase II results from the company's fully enrolled 403 trial, which was comprised of patients with metastatic or locally advanced unresectable soft tissue sarcoma who were not previously received…